Moderna (MRNA) Will Host Conference Call on Phase 1 Interim Analysis for mRNA Flu Vaccine on Friday, December 10

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it will host a live conference call and webcast on the Phase 1 interim analysis of its seasonal influenza vaccine candidate, mRNA-1010 tomorrow, Friday, December 10, 2021 at 8:00 a.m. ET.

To access the call, please dial 866-922-5184 (domestic) or 409-937-8950 (international) and refer to conference ID 8748887. A webcast of the call will also be available under “Events and Presentations” in the Investors section of the Moderna website at investors.modernatx.com. The archived webcast will be available on Moderna’s website approximately two hours after the conference call.

You May Also Be Interested In

• Wolfe Research Upgrades Moderna (MRNA) to Peerperform
• AWS and Nvidia plan to deploy 2 million more GPUs in 2027-2028
• Alleima extends Airbus supply agreement to longest term in partnership history